Literature DB >> 20170725

Different in vitro toxicities of structurally similar type I ribosome-inactivating proteins (RIPs).

Ou Sha1, David Tai Wai Yew, Tzi Bun Ng, Lin Yuan, Wing Hang Kwong.   

Abstract

This study was aimed at investigating and comparing the cytotoxicities of two structurally similar type I RIPs, namely trichosanthin (TCS) and free ricin A chain (RTA). A type II RIP, namely Ricinus communis agglutinin (RCA), was also included for comparison. The three RIPs were added separately to cultures of NIH 3T3 cells. The effective doses and time courses were analyzed using cell counts. Polyclonal antibodies against TCS and RTA were produced in rabbits and purified by a protein A-Sepharose CL-4B column. The mechanisms of cell death were determined by TUNEL, immunohistochemical staining, flow cytometry, and Western blotting. The effective doses for TCS, RTA and RCA were found to be 800, 50, and 50 nM, respectively. All three RIPs induced apoptosis. In all cases, activation of caspase-3 and caspase-8, but not caspase-9, was detected. Additionally, RTA caused in vivo tissue necrosis in rabbits after intradermal administration. Hence the mechanism of cell death due to RTA intoxication may vary depending on the experimental conditions, being necrosis in vivo and apoptosis in vitro. The present findings may shed light on the apoptotic pathway induced by RIPs. RTA may be useful for studying the shift in cell death. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20170725     DOI: 10.1016/j.tiv.2010.02.014

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  8 in total

1.  Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL.

Authors:  Hassan Adwan; Ahmed Murtaja; Khamael Kadhim Al-Taee; Asim Pervaiz; Thomas Hielscher; Martin R Berger
Journal:  Cancer Biol Ther       Date:  2014-06-11       Impact factor: 4.742

Review 2.  Potential therapeutic applications of plant toxin-ricin in cancer: challenges and advances.

Authors:  Nikhil Tyagi; Monika Tyagi; Manendra Pachauri; Prahlad C Ghosh
Journal:  Tumour Biol       Date:  2015-09-09

3.  The anti-cancerous activity of recombinant trichosanthin on prostate cancer cell PC3.

Authors:  JinLong Li; Hui Li; ZhaoLi Zhang; NianYue Wang; YongChen Zhang
Journal:  Biol Res       Date:  2016-03-25       Impact factor: 5.612

4.  Trichosanthin enhances the antitumor effect of gemcitabine in non-small cell lung cancer via inhibition of the PI3K/AKT pathway.

Authors:  Naren Tuya; Yadi Wang; Lanmei Tong; Weishi Gao; Rong Yu; Liying Xue
Journal:  Exp Ther Med       Date:  2017-10-11       Impact factor: 2.447

Review 5.  Intracellular Transport and Cytotoxicity of the Protein Toxin Ricin.

Authors:  Natalia Sowa-Rogozińska; Hanna Sominka; Jowita Nowakowska-Gołacka; Kirsten Sandvig; Monika Słomińska-Wojewódzka
Journal:  Toxins (Basel)       Date:  2019-06-18       Impact factor: 4.546

Review 6.  Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review.

Authors:  Ou Sha; Junfei Niu; Tzi-Bun Ng; Eric Yu-Pang Cho; Xiaoyuan Fu; Wenqi Jiang
Journal:  Cancer Chemother Pharmacol       Date:  2013-02-03       Impact factor: 3.333

7.  Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis.

Authors:  Evandro Fei Fang; Chris Zhi Yi Zhang; Lin Zhang; Jack Ho Wong; Yau Sang Chan; Wen Liang Pan; Xiu Li Dan; Cui Ming Yin; Chi Hin Cho; Tzi Bun Ng
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

8.  Trichosanthin enhances sensitivity of non-small cell lung cancer (NSCLC) TRAIL-resistance cells.

Authors:  Chengcheng You; Yingming Sun; Shiyu Zhang; Guiliang Tang; Nannan Zhang; Chunyang Li; Xiaoli Tian; Shijing Ma; Yuan Luo; Wenjie Sun; Feng Wang; Xuefeng Liu; Yu Xiao; Yan Gong; Junhong Zhang; Conghua Xie
Journal:  Int J Biol Sci       Date:  2018-02-09       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.